StockNews.com Begins Coverage on vTv Therapeutics (NASDAQ:VTVT)

StockNews.com assumed coverage on shares of vTv Therapeutics (NASDAQ:VTVT) in a research report report published on Sunday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Separately, Alliance Global Partners began coverage on shares of vTv Therapeutics in a research note on Monday, December 9th. They issued a “buy” rating and a $35.00 target price on the stock.

vTv Therapeutics Trading Down 3.0 %

Shares of vTv Therapeutics stock opened at $19.27 on Friday. The company’s 50-day moving average price is $15.84 and its 200-day moving average price is $15.19. vTv Therapeutics has a 12-month low of $8.10 and a 12-month high of $30.99. The company has a market cap of $61.46 million, a price-to-earnings ratio of -4.25 and a beta of 0.73.

Hedge Funds Weigh In On vTv Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in VTVT. JPMorgan Chase & Co. purchased a new stake in shares of vTv Therapeutics in the 4th quarter valued at about $25,000. Geode Capital Management LLC grew its holdings in shares of vTv Therapeutics by 12.9% during the fourth quarter. Geode Capital Management LLC now owns 11,634 shares of the biotechnology company’s stock worth $158,000 after purchasing an additional 1,327 shares in the last quarter. Finally, FMR LLC bought a new position in shares of vTv Therapeutics in the third quarter worth approximately $2,402,000. 17.51% of the stock is currently owned by hedge funds and other institutional investors.

About vTv Therapeutics

vTv Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on the development of orally administered treatments for metabolic and inflammatory diseases. The company's lead drug candidate is cadisegliatin (TTP399), an orally administered small molecule and liver-selective glucokinase activator that is in Phase III clinical trial for treating type 1 and type 2 diabetes; and TTP273, an orally available small molecule glucagon-like peptide 1 receptor agonists that is in Phase I clinical trial for the treatment of cystic fibrosis related diabetes, as well as in Phase II trial for the treatment of type 2 diabetes.